Colchicine Reduces Cardiovascular Events in Patients with Diabetes and Recent MI

The benefit was greater in a subset of patients with type 2 diabetes than in all patients with CAD.

In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes trial (COLCOT), use of low-dose colchicine (0.5 mg daily) reduced cardiovascular events in 4745 patients with a recent acute myocardial infarction (MI; NEJM JW Cardiol Nov 16 2019 and N Engl J Med 2019; 381:2497). Now, the trial investigators have conducted a prespecified subgroup analysis in patients with type 2 diabetes mellitus (T2DM).

In the primary analysis of COLCOT, compared with the placebo group, the colchicine group had a 23% reduced risk (absolute risk, 5.5% vs. 7.1%) for the primary endpoint — a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, and urgent hospitalization for angina requiring revascularization. Among the 959 particip…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)